Background: Sodium-glucose co-transporter 2 (SGLT2) are medications approved for treatment of type 2 diabetes. Recent evidence suggests that these agents exert Reno protective effects

Nasser Mikhail
Additional contact information
Nasser Mikhail: Endocrinology Division, David-Geffen UCLA School of Medicine, USA

Current Research in Diabetes & Obesity Journal, 2019, vol. 12, issue 3, 55-60

Abstract: Chronic kidney disease (CKD) occurs in approximately 40% of patients with type 2 diabetes and contributes to approximately 50% of ESKD [1]. SGLT2 inhibitors represent a class of anti-diabetic agents that decrease hyperglycemia independently of insulin by lowering the renal threshold for glucose and therefore increasing urinary excretion of glucose [2].

Keywords: juniper publishers; diabetes journals; diabetes impact factor; endocrinology journal; endocrinology impact factor; endocrinology research journal; endocrinology research articles; diabetes open access journals; Obesity Journal; Diabetes & Obesity Journal (search for similar items in EconPapers)
Date: 2019
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://juniperpublishers.com/crdoj/pdf/CRDOJ.MS.ID.555839.pdf (application/pdf)
https://juniperpublishers.com/crdoj/CRDOJ.MS.ID.555839.php (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:adp:jcrdoj:v:12:y:2019:i:3:p:55-60

DOI: 10.19080/CRDOJ.2019.11.555839

Access Statistics for this article

Current Research in Diabetes & Obesity Journal is currently edited by Sophia Mathis

More articles in Current Research in Diabetes & Obesity Journal from Juniper Publishers Inc.
Bibliographic data for series maintained by Robert Thomas ().